NCT04313166

Treatment Continuation Study for Patients With ALS/MND Who Completed Study CMD-2019-001

A Treatment Continuation Study for Patients With Amyotrophic Lateral Sclerosis/Motor Neuron Disease Who Have Successfully Complete Study CMD-2019-001

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 55 (actual)
• Sponsor: Collaborative Medicinal Development Pty Limited · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

Provides up to six months treatment with CuATSM for subjects who have successfully completed study CMD-2019-001

Detailed description

Provides up to six months treatment with CuATSM for subjects who have successffulyl completed study CMD-2019-001. \[This allows subjects randomized to placebo on study CMD-2019-001 to receive up to six months treatment with CuATSM and provides an up to an additional six months treatment with CuATSM for subjects randomized to CuATSM on study CMD-2019-001\]

Conditions

• Amyotrophic Lateral Sclerosis

Interventions

Type	Name	Description
DRUG	Cu(II)ATSM	cooper-containing synthetic small molecule

Timeline

• Start date: 2020-03-19
• Primary completion: 2021-11-18
• Completion: 2022-02-15
• First posted: 2020-03-18
• Last updated: 2022-02-17

Locations

1 site across 1 country: Australia